Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposome in platinum-treated SCLC
NCT04727853Phase 2Completed
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- Mar 2021
- Primary completion
- Apr 2022
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan liposome in small cell lung cancer (SCLC), sponsored by CSPC Ouyi Pharmaceutical. Started Mar 2021; status: completed.
02
Drugs
irinotecan liposome
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04727853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04727853.